<DOC>
	<DOC>NCT01465763</DOC>
	<brief_summary>This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.</brief_summary>
	<brief_title>A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subject must be at least 18 years of age. Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study. Subjects with moderately to severely active UC based on Mayo score criteria. Subjects must have failed or be intolerant of at least one of the following treatments for UC: Corticosteroids (oral or intravenous). Azathioprine or 6 mercaptopurine (6 MP). Anti TNFalpha therapy. Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease. Subjects with disease limited to distal 15 cm. Subjects without previous treatment for UC (ie, treatment na√Øve). Subjects displaying clinical signs of fulminant colitis or toxic megacolon.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Moderate to severe ulcerative colitis</keyword>
	<keyword>phase 3 clinical trial</keyword>
	<keyword>Mayo score</keyword>
</DOC>